CAP 004
Alternative Names: CAP-004Latest Information Update: 17 Sep 2024
At a glance
- Originator Capsida Biotherapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 30 Aug 2024 Early research in Unspecified in USA (IV) prior to August 2024 (Capsida Biotherapeutics pipeline, August 2024)